Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Irish Journal of Medical Science (1971 -)
Published in: Irish Journal of Medical Science (1971 -) 1/2013

01-03-2013 | Original Article

Immunomodulators for multiple sclerosis may ameliorate spinal bone loss

Authors: M. J. McKenna, B. Murray, R. Lonergan, J. M. T. Redmond

Published in: Irish Journal of Medical Science (1971 -) | Issue 1/2013

Login to get access

Abstract

Background

The effect of immunomodulator therapy (IMT) for multiple sclerosis (MS) on bone turnover is unknown.

Aim

The aim of this study was to assess bone turnover in MS patients on IMT.

Methods

MS patients (n = 29) on maintenance IMT had repeat measurement of bone mineral density (BMD) after a 4.0 ± 0.4 years; bone turnover markers (BTM) were measured at the time of repeat BMD.

Results

BMD was unchanged at the spine but declined at the hip. BTMs, both resorption and formation, were reduced compared to normative range that may indicate an anti-resorptive action of IMT. Significant negative correlations were noted between BTMs and changes in BMD at spine but not hip.

Conclusion

These observations suggest that IMT may have a beneficial effect on spinal bone by an antiresorptive action. A prospective study of the effect of IMT on BMD and bone turnover is warranted.
Literature
1.
Reder AT, Ebers GC, Traboulsee A et al (2010) Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 74:1877–1885PubMedCrossRef
2.
Shuhaibar M, McKenna MJ, Au-Yeong M, Redmond JM (2009) Favorable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci 178:43–45PubMedCrossRef
3.
Kampman MT, Steffensen LH (2009) Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis. Ir J Med Sci 178:235–236; author reply 237–238
4.
Varoglu AO, Varoglu E, Bayraktar R, Aygul R, Ulvi H, Yildirim K (2010) The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients. J Back Musculoskelet Rehabil 23:25–29PubMed
5.
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452PubMedCrossRef
6.
McKenna MJ, van der Kamp S, Au-Yeong M, FitzGerald O (2008) Improving standards of DXA. Ir Med J 101:101–102PubMed
7.
Looker AC, Wahner HW, Dunn WL et al (1995) Proximal femur bone mineral levels of US adults. Osteoporos Int 5:389–409PubMedCrossRef
8.
Nanda KS, Ryan EJ, Murray BF et al (2009) Effect of chronic hepatitis C virus infection on bone disease in postmenopausal women. Clin Gastroenterol Hepatol 7:894–899PubMedCrossRef
9.
Ryan C, Moran B, McKenna MJ et al (2010) The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland. Arch Dermatol 146:836–842PubMedCrossRef
10.
Daly LE, Bourke JB, McGilvray J (1991) Interpretation and uses of medical statistics. Blackwell Scientific Publications, London
11.
Katz M (2006) Multivariable Analysis. A Practical Guide for Clinicians. Cambridge University Press, CambridgeCrossRef
12.
Lorenzo J (2011) The effects of immune cell products (cytokines and hematopoietic cell growth factors) on bone cells. In: Lorenzo J, Choi Y, Horowitz M, Takayanagi H (eds) Osteoimmunology. Academic Press, London, pp 187–225
13.
Takayanagi H, Kim S, Matsuo K et al (2002) RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 416:744–749PubMedCrossRef
14.
Weinstock-Guttman B, Hong J, Santos R et al (2006) Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler 12:541–550PubMedCrossRef
15.
Lonergan R, Kinsella K, Fitzpatrick P et al (2011) Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. J Neurol Neurosurg Psychiatry 82:317–322PubMedCrossRef
16.
McKenna M, Freaney R, Keating D, Muldowney FP (1981) The prevalence and management of vitamin D deficiency in an acute geriatric unit. Ir Med J 74:336–338PubMed
17.
Parfitt AM, Gallagher JC, Heaney RP, Johnston CC, Neer R, Whedon GD (1982) Vitamin D and bone health in the elderly. Am J Clin Nutr 36:1014–1031PubMed
18.
McKenna MJ (1992) Differences in vitamin D status between countries in young adults and the elderly. Am J Med 93:69–77PubMedCrossRef
19.
Ross AC, Manson JE, Abrams SA et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53–58PubMedCrossRef
20.
Aloia JF (2011) The 2011 report on dietary reference intake for vitamin D: where do we go from here? J Clin Endocrinol Metab 96:2987–2996PubMedCrossRef
Metadata
Title
Immunomodulators for multiple sclerosis may ameliorate spinal bone loss
Authors
M. J. McKenna
B. Murray
R. Lonergan
J. M. T. Redmond
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Irish Journal of Medical Science (1971 -) / Issue 1/2013
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-012-0818-5

Other articles of this Issue 1/2013

Irish Journal of Medical Science (1971 -) 1/2013 Go to the issue

Review Article

Difficulties with percutaneous endoscopic gastrostomy (PEG): a practical guide for the endoscopist

Original Article

Pulmonary infections imitating lung cancer: clinical presentation and therapeutical approach

Original Article

The cost utility of a multi-disciplinary foot protection clinic (MDFPC) in an Irish hospital setting

Original Article

In-situ emergency pediatric surgery in the intensive care unit

Literary and Historical

First ladies in laying the foundation of neuroendocrinology

Original Article

Has your work worked you too hard? Physically demanding work and disability in a sample of the older Irish population
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits